Small molecule (Molecular glue degrader) · Degrader of Bruton's tyrosine kinase (BTK) · developed by Nurix Therapeutics
Bexobrutideg (NX-5948) is an orally bioavailable chimeric targeting molecule that links a cereblon-binding moiety to a BTK-binding moiety. It recruits the CRL4-CRBN E3 ubiquitin ligase to BTK, driving its ubiquitination and proteasomal degradation. It is being studied in B-cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07516093 | Phase 3 | B-cell Lymphoma | Recruiting | NRIX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the NRIX page.
See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NRIX catalysts and pipeline →